Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders for Innoviva, Inc. held on June 17, 2024. The company is incorporated in Delaware and trades on the NASDAQ Global Select Market under the symbol INVA.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of three key matters submitted to a vote of security holders:
- Board of Directors Election: Six directors were elected for one-year terms expiring in 2025. Voting results were as follows:
- Mark DiPaolo, Esq.: 52,630,405.53 For; 1,369,108 Against/Abstained.
- Jules Haimovitz: 52,638,945.53 For; 1,360,568 Against/Abstained.
- Odysseas D. Kostas, M.D.: 53,558,321.53 For; 441,192 Against/Abstained.
- Sarah Schlesinger, M.D.: 52,024,328.53 For; 1,975,185 Against/Abstained.
- Derek Small: 53,731,768.53 For; 267,745 Against/Abstained.
- Sapna Srivastava, Ph.D.: 48,313,815.53 For; 5,685,698 Against/Abstained.
- Executive Compensation (Say-on-Pay): Stockholders approved executive compensation on a non-binding advisory basis.
- For: 52,833,150.39 shares
- Against: 1,146,788 shares
- Abstained: 19,575.14 shares
- Auditor Ratification: Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- For: 56,265,724.95 shares
- Against: 271,022 shares
- Abstained: 7,138 shares
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting results.
Investor Verification Checklist
- Verify the total number of shares outstanding and the percentage of votes cast against the election of Sapna Srivastava, Ph.D., which was notably higher than other nominees.
- Confirm the term expiration dates for the newly elected board members (2025).
- Review the company's most recent 10-K or 10-Q for financial performance metrics, as this 8-K contains no financial data.
- Check for any subsequent filings regarding the implementation of the approved executive compensation plan.